TG ImmunoPharma announced its completion of pre-Series A financing round valued at hundreds of millions of CNY. This round was led by Casstar and Innoval Capital. Other investors including Hefei Industry Investment Capital, Efung Capital, Tiantu Capital and Guoyuan Innovating Investment also participated in this deal. The funding will be used to accelerate the development and registration of multiple product pipelines.
As a wholly-owned subsidiary of Guoyuan Securities, Guoyuan Innovating Investment has a registered capital of 1.5 billion yuan, mainly focusing on project and equity investment. By upholding the corporate spirit of “working hard with down-to-earth attitude and a sense of responsibility”, the company creates a sound business environment with the business philosophy of honesty and mutual-benefit. It attaches great importance to new management modes, refined technology, thoughtful service and excellent quality as its foundation for survival, with its investment in such listed companies as Zeho Eco, QuantumCTek, Jee Technology, Kewell, Ronds, Gocom, Yuanchen Envirn and Tongyuan Environment.
Hefei Industry Investment Capital under Hefei Industry Investment Group focuses on the strategic layout of the city's leading industries, with emphasis on integrated circuits, panel displays, new energy vehicles and biomedicine. It currently houses 22 industry investment capital management funds, and the scale of self-managed funds exceeds 10 billion yuan, with a cumulative support of 220 projects and an investment volume of 21.993 billion yuan. In terms of the biomedical field, it has invested in Haisen Pharma (acquired by Takeda), Hefei Breath Medical, Hina Digital Technology, Knature Pharmaceutical, Jingze Pharma, Ray Solution, Elite Pharma Technology and Starry Gene, thereby injecting capital momentum for the development of enterprises in the biomedical industry in our city.